跳至主要内容
临床试验/NCT03212456
NCT03212456Unknown不适用

Evaluation of Post-operative Biochemical Recurrence in Patients Submitted to Radical Prostatectomy Under General Opioid-free Anesthesia Compared to Conventional General Anesthesia

Instituto do Cancer do Estado de São Paulo1 个研究点 分布在 1 个国家目标入组 146 人开始时间: 2017年1月12日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
146
试验地点
1
主要终点
Biochemical recurrence of prostate cancer

研究概览

简要总结

The use of opioids facilitates angiogenesis and has a proven action in the immune system, mainly in the reduction of natural killer cell activity, favoring the migration of neoplastic cells and inhibiting humoral and cellular immunity. These factors may contribute to recurrence and tumor metastasis.

Therefore, could opioid-free anesthesia help reduce tumor recurrence? This is a prospective randomized controlled clinical trial in which patients undergoing radical prostatectomy will be evaluated by conventional means, which have moderate and high D'Amico criteria for tumor recurrence.

In the operating room, patients will be monitored, receive peripheral venoclysis and then randomized into two groups: in group I, the anesthetic induction will be done with pre oxygenation with 100% O2, propofol, cisatracurium, lidocaine and fentanyl; In group II the induction will be done with the same doses of propofol, cisatracurium, lidocaine and placebo.

In both groups maintenance of general anesthesia will be with propofol 1% target infusion controlled with model of Marsh target-controlled infusion plasma between 2.0 and 3.0 mcg / ml, ketamine, lidocaine and dexmedetomidine.

Both groups will receive blockade of the transverse plane of the ultrasound guided ultrasound, group I with placebo (saline 0.9% 20 ml on each side) and group II with ropivacaine 0.375% 20 ml on each side. And the postoperative analgesia will be based on anti-inflammatory and opioid analgesics (pca of morphine) according to the analgesic pain scale of the patients.

In the postoperative period, patients will be followed up for 2 years with serial doses of prostate specific antigen (PSA) to diagnose tumor recurrence (2 PSA measures> 0.2 ng / ml) and will be evaluated in relation to analgesia, need for analgesia of Rescue with morphine, satisfaction with the anesthetic technique, adverse effects (nausea and vomiting).

The primary objective is to evaluate tumor biochemical recurrence after radical prostatectomy in patients undergoing opioid anesthesia compared to patients anesthetized without opioids. The secondary objectives are to evaluate the quality of analgesia with the two techniques, patient satisfaction with perioperative period, quality of anesthetic recovery and adverse effects (nausea and vomiting, pruritus and drowsiness).

Thus, to answer the hypothesis raised, 146 patients will be needed (73 in each group).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Prostate Cancer;
  • Intermediate to high risk of recurrence by D'Amico criteria (Gleason scale > or = 7; PSA > or = 10)

排除标准

  • Patient refuse;
  • atrioventricular blockade;
  • Coagulopathy;
  • Other procedure at same time.

研究组 & 干预措施

Opioid-free

Experimental

The patients of this group will receive opioid-free anesthesia

干预措施: opioid-free group (Drug)

Opioid-free

Experimental

The patients of this group will receive opioid-free anesthesia

干预措施: transversus abdominal plane block with ropivacaine (Procedure)

Non opioid-free

Active Comparator

The patients in this group will receive the same induction and maintenance drugs of the experimental group but with fentanyl 3 - 5 mcg/kg on induction and during the procedure as needed.

干预措施: Opioid Group (Drug)

Non opioid-free

Active Comparator

The patients in this group will receive the same induction and maintenance drugs of the experimental group but with fentanyl 3 - 5 mcg/kg on induction and during the procedure as needed.

干预措施: transversus abdominal plane block with placebo (Procedure)

结局指标

主要结局

Biochemical recurrence of prostate cancer

时间窗: Up to 2 years after the date of the surgery

It's going to be measured the prostate specific antigen in 4 times after the date of the surgery( 6 months, 1 year, 1 and a half year and 2 years after the surgery) to compare elevations between the two groups.

次要结局

  • Satisfaction with anesthesia technique(Up to 2 hours postoperatively)
  • Neutrophil-to-lymphocyte ratio(24 hour postoperatively)
  • adverse outcomes(Up to 2 hours postoperatively)
  • visual analogue pain score in the post-anaesthesia care unit(Up to 2 hours postoperatively)
  • Rescue Morphine(Up to 2 hours postoperatively)

研究者

发起方
Instituto do Cancer do Estado de São Paulo
申办方类型
Other
责任方
Principal Investigator
主要研究者

Felipe Rangel

MD, Anesthesiologist, principal investigator

Instituto do Cancer do Estado de São Paulo

研究点 (1)

Loading locations...

相似试验